• Prime Medicine priced an underwritten public offering of 35,714,286 common shares at $3.50 per share.
• Expected gross proceeds total approximately $125 million before underwriting discounts, commissions and offering expenses, excluding the underwriters' option.
• Underwriters received a 30-day option to purchase up to 5,357,142 additional common shares.
• The offering is expected to close on or about November 12, 2026, subject to customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611102140PRIMZONEFULLFEED9875196) on November 11, 2026, and is solely responsible for the information contained therein.